Advertisement
UK markets close in 3 hours 28 minutes

  • FTSE 100

    8,232.61
    +27.50 (+0.34%)
     

  • FTSE 250

    20,443.74
    +62.69 (+0.31%)
     

  • AIM

    774.49
    -3.01 (-0.39%)
     

  • GBP/EUR

    1.1834
    -0.0000 (-0.00%)
     

  • GBP/USD

    1.2681
    -0.0040 (-0.32%)
     

  • Bitcoin GBP

    52,159.90
    +759.80 (+1.48%)
     

  • CMC Crypto 200

    1,375.25
    -7.41 (-0.54%)
     

  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     

  • DOW

    38,834.86
    +56.76 (+0.15%)
     

  • CRUDE OIL

    81.73
    +0.16 (+0.20%)
     

  • GOLD FUTURES

    2,352.20
    +5.30 (+0.23%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • HANG SENG

    18,335.32
    -95.07 (-0.52%)
     

  • DAX

    18,155.30
    +87.39 (+0.48%)
     

  • CAC 40

    7,638.90
    +68.70 (+0.91%)
     
Money:

Best UK mortgage deals of the week

Average two-year mortgage deal is now around 6%

Senseonics Holdings, Inc. to Host Business Update and Analyst Event During the American Diabetes Association’s 84th Scientific Sessions

Business Wire
·1-min read

GERMANTOWN, Md., June 13, 2024--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to host a business update and analyst event during the American Diabetes Association’s 84th Scientific Sessions in Orlando, FL.

Breakfast and refreshments will be provided beginning at 9:15 am ET on Sunday, June 23, 2024, in advance of a business update presentation from management scheduled to begin, at 10:00 am ET. Interested parties may access a live and recorded webcast of the presentation on the "Investor Relations" section of the company’s website at www.senseonics.com.

In-person attendance for the event requires advanced registration. Please email Hannah Jeffrey at hannah@gilmartinir.com by June 21, 2024, to register.

ADVERTISEMENT

About Senseonics

Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics’ CGM system Eversense® E3 includes a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user’s smartphone.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240613143680/en/

Contacts

Senseonics Investor Contact
Philip Taylor
Gilmartin Group
415-937-5406
Investors@senseonics.com